330 related articles for article (PubMed ID: 29884437)
41. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
42. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.
Stern JW; Bunin N
Med Pediatr Oncol; 2002 Sep; 39(3):163-7. PubMed ID: 12210444
[TBL] [Abstract][Full Text] [Related]
43. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
[TBL] [Abstract][Full Text] [Related]
44. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
45. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
Billmire D; Vinocur C; Rescorla F; Cushing B; London W; Schlatter M; Davis M; Giller R; Lauer S; Olson T;
J Pediatr Surg; 2004 Mar; 39(3):424-9; discussion 424-9. PubMed ID: 15017564
[TBL] [Abstract][Full Text] [Related]
46. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
47. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
48. Malignant ovarian germ cell tumors: a review of thirty-six cases.
Micha JP; Kucera PR; Berman ML; Romansky S; Flamm M; Reynolds J; DiSaia PJ
Am J Obstet Gynecol; 1985 Aug; 152(7 Pt 1):842-6. PubMed ID: 2411136
[TBL] [Abstract][Full Text] [Related]
49. [A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy].
Ishibashi M; Nakayama K; Oride A; Yeasmin S; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gan To Kagaku Ryoho; 2009 Mar; 36(3):513-7. PubMed ID: 19295284
[TBL] [Abstract][Full Text] [Related]
50. Advanced stage of dysgerminoma in testicular feminisation: is radical surgery necessary?
Chan LY; Wong SF; Yu VS
Aust N Z J Obstet Gynaecol; 2000 May; 40(2):224-5. PubMed ID: 10925918
[No Abstract] [Full Text] [Related]
51. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
52. [Characteristics of rare ovarian tumors--possibilities of organ preservation].
Grischke EM; Wallwiener D; Bastert G
Zentralbl Gynakol; 1996; 118(6):322-5. PubMed ID: 8768007
[TBL] [Abstract][Full Text] [Related]
53. Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary.
Kasenda B; Harter P; Hirsch T; Ast A; Buhrmann C; Glaser F; Du Bois A
Acta Obstet Gynecol Scand; 2009; 88(11):1288-90. PubMed ID: 19900144
[TBL] [Abstract][Full Text] [Related]
54. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
55. Malignant ovarian germ cell tumors: a single-institution experience.
Cicin I; Eralp Y; Saip P; Ayan I; Kebudi R; Iyibozkurt C; Tuzlali S; Gorgun O; Topuz E
Am J Clin Oncol; 2009 Apr; 32(2):191-6. PubMed ID: 19307952
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
57. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
58. [Adjuvant chemotherapy in dysgerminoma].
Fechtig A; de Dycker RP; Schumacher T; Neumann RL
Geburtshilfe Frauenheilkd; 1991 May; 51(5):398-400. PubMed ID: 1869011
[TBL] [Abstract][Full Text] [Related]
59. [Mixed germ cell tumours of the ovary in childhood and adolescence].
Zuntová A; Sumerauer D; Teslík L; Kabícková E; Koutecký J
Cesk Patol; 2004 Jul; 40(3):92-101. PubMed ID: 15493415
[TBL] [Abstract][Full Text] [Related]
60. Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb K
Gynecol Oncol; 2017 Dec; 147(3):493-496. PubMed ID: 29021083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
